Search for a trial

An open label Phase I PET imaging study to investigate the bio-distribution and tumor uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are treated with ezabenlimab

This study has been transitioned to CTIS with ID 2024-514034-20-00 check the CTIS register for the current data. The primary objective is to estimate the average relative change from baseline in tumoruptake of [89Zr]Zr-BI 765063 (arm A) or [89Zr]Zr-…

A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors

This study has been transitioned to CTIS with ID 2024-511352-41-00 check the CTIS register for the current data. To investigate the maximum tolerated dose (MTD) of BI 907828 in combination with ezabenlimab based on dose limiting toxicities (DLT)…